Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

Thrombosis Journal

Review

Raul Altman¹  Hector O Vidal² 

[1] Centro de Trombosis de Buenos Aires, Viamonte 2008,1056 Buenos Aires, Argentina;Hospital Italiano de La Plata, Area de Hematología, Sección Hemostasia y Trombosis, 1900 La Plata,Pcia. de Buenos Aires, Argentina;

关键词: Atrial fibrillation;    Oral anticoagulants;    Antiplatelet drugs;    Aspirin;    Dabigatran;    Rivaroxaban;    Apixaban;   

DOI  :  10.1186/1477-9560-9-12

 received in 2011-07-18, accepted in 2011-07-27,  发布年份 2011

来源: Springer

【 摘 要 】

Warfarin has a long history of benefit and has become the gold standard medication for the prevention of ischemic stroke in patients with atrial fibrillation. Nevertheless, it is far from perfect and there is no doubt that new drugs must be found to replace warfarin. The new oral anticoagulants that are on the market or awaiting approval or under research offer some benefits but not enough to replace warfarin until results of additional studies can show an adequate balance between effectiveness/safety and cost/benefit. There are several issues concerning the new oral anticoagulants. It is essential that the effect of any anticoagulant can be measured in plasma. But to date, there is no test to assess the effect or therapeutic range for the new oral anticoagulants. There is no antidote to neutralize the action of the new drugs in cases of bleeding or when acute surgical intervention is necessary. Dabigatran requires dose adjustment in patients with moderate renal impairment and is contraindicated in patients with severe renal failure. Rivaroxaban should be used with caution in patients with severe renal impairment. Apixaban excretion is also partly dependent on renal function, although the impact of renal insufficiency has not yet been determined. How anticoagulant bridging can be done before surgery has not yet been established. In conclusion, although thousands of patients have been treated in phase III studies, additional data are necessary before conclusions can be drawn on the potential for these new anticoagulant drugs to replace warfarin in patients with atrial fibrillation.

【 授权许可】

CC BY   
© Altman and Vidal; licensee BioMed Central Ltd. 2011